PMID- 32494334
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 1925-8348 (Print)
IS  - 1925-8348 (Electronic)
IS  - 1925-8348 (Linking)
VI  - 23
IP  - 2
DP  - 2020 Jun
TI  - Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in 
      Older Patients Treated for Rheumatoid Arthritis.
PG  - 184-189
LID - 10.5770/cgj.23.393 [doi]
AB  - BACKGROUND: Biological disease-modifying antirheumatic drugs (bDMARDs) are 
      recommended for rheumatoid arthritis (RA), but older patients reportedly 
      experience more adverse events (AEs) and show variable treatment response. The 
      objective of this study was to evaluate AEs and effectiveness of bDMARDs in a 
      cohort of older patients. METHODS: AE and treatment effectiveness (based on DAS28 
      scores) data from a prospective provincial pharmacovigilance program for the 
      years 2006-2009 in patients 55-64, 65-74, and 75+ years of age were compared. An 
      intention to treat analysis with chi-square and unpaired t-testing for 
      significance was performed. RESULTS: There were a total of 333 patients (156 were 
      aged 55-64, 125 were 65-74, 52 were 75+). Those 75+ had higher disease activity 
      and worse functional status at baseline. Among those 75+, AEs with bDMARDs were 
      more common and likely to lead to discontinuation of therapy, be graded as 
      severe, and classified as infectious (p < .05). Remission rate among those 75+ 
      was significantly higher than patients 65-74. Etanercept was the most commonly 
      used drug in all age groups. CONCLUSION: Patients 75+ treated with bDMARDs are at 
      a significantly greater risk of AEs, including infectious ones. The higher 
      remission found in the oldest age group warrants further study.
CI  - (c) 2020 Author(s). Published by the Canadian Geriatrics Society.
FAU - Akter, Ripa
AU  - Akter R
AD  - Geriatrics, Internal Medicine, Division of Geriatric Medicine, University of 
      Ottawa, Ottawa, ON, Canada.
FAU - Maksymowych, Walter P
AU  - Maksymowych WP
AD  - Division of Rheumatology, Department of Medicine, Faculty of Medicine & 
      Dentistry, University of Alberta, Edmonton, AB, Canada.
FAU - Martin, M Liam
AU  - Martin ML
AD  - Division of Rheumatology, Department of Medicine, Cumming School of Medicine, 
      University of Calgary, Calgary, AB, Canada.
FAU - Hogan, David B
AU  - Hogan DB
AD  - Geriatrics, Internal Medicine, Division of Geriatric Medicine, University of 
      Ottawa, Ottawa, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - Canada
TA  - Can Geriatr J
JT  - Canadian geriatrics journal : CGJ
JID - 101579189
PMC - PMC7259924
OTO - NOTNLM
OT  - adverse events
OT  - biological disease-modifying anti-rheumatic drugs
OT  - effectiveness
OT  - late onset rheumatoid arthritis
OT  - older age
OT  - rheumatoid arthritis
OT  - safety
COIS- CONFLICT OF INTEREST DISCLOSURES The authors declare that no conflicts of 
      interest exist.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
PMCR- 2020/06/01
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - cgj-23-184 [pii]
AID - 10.5770/cgj.23.393 [doi]
PST - epublish
SO  - Can Geriatr J. 2020 May 1;23(2):184-189. doi: 10.5770/cgj.23.393. eCollection 
      2020 Jun.